Evidence map›Paper›PMID 39385245›Full record

ArticleBiomarker research2024

Skin-permeable gold nanoparticles with modifications azelamide monoethanolamine ameliorate inflammatory skin diseases.

He Zhao, Han Zhao, Yan Tang, Mengfan Li, Yisheng Cai, Xin Xiao, Fanping He, Hongwen Huang, Yiya Zhang, Ji Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomarker research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Melittin-Loaded FeInternational journal of nanomedicine · 2026
    Article
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

He Zhao *Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China.
Han Zhao *Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China.
Yan TangDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha, China.
Mengfan LiCollege of Materials Science and Engineering, Hunan University, Changsha, Hunan, 410082, P. R. China.
Yisheng CaiDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha, China.
Xin XiaoDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha, China.
Fanping HeDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha, China.
Hongwen HuangCollege of Materials Science and Engineering, Hunan University, Changsha, Hunan, 410082, P. R. China. huanghw@hnu.edu.cn.
Yiya ZhangDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha, China. yiya0108@csu.edu.cn.
Ji LiDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha, China. liji_xy@csu.edu.cn.

Funding

National Key Research and Development Program of China No.2021YFF1201205National Natural Science Foundation of China 82273557National Natural Science Funds for Distinguished Young Scholars 82225039National Natural Sciences Foundation of Hunan province 2024JJ5577
6 · The paper itself

Abstract

backgroundTraditional topical drug delivery for treating inflammatory skin diseases suffers from poor skin penetration and long-term side effects. Metal nanoparticles show promising application in topical drug delivery for inflammatory skin diseases.

methodsHere, we synthesized a new type of nanoparticles, azelamide monoethanolamine-functionalized gold nanoparticles (Au-MEA NPs), based on citrate-capped gold nanoparticles (Au-CA NPs) via the ligand exchange method. The physical and chemical properties of Au-CA NPs and Au-MEA NPs were characterized. In vivo studies were performed using imiquimod-induced psoriasis and LL37-induced rosacea animal models, respectively. For in vitro studies, a model of cellular inflammation was established using HaCaT cells stimulated with TNF-α. In addition, proteomics, gelatin zymography, and other techniques were used to investigate the possible therapeutic mechanisms of the Au-MEA NPs.

resultsWe found that Au-MEA NPs exhibited better stability and permeation properties compared to conventional Au-CA NPs. Transcutaneously administered Au-MEA NPs exerted potent therapeutic efficacy against both rosacea-like and psoriasiform skin dermatitis in vivo without overt signs of toxicity. Mechanistically, Au-MEA NPs reduced the production of pro-inflammatory mediators in keratinocytes by promoting SOD activity and inhibiting the activity of MMP9.

conclusionAu-MEA NPs have the potential to be a topical nanomedicine for the effective and safe treatment of inflammatory skin diseases.

Indexed as

Azelamide monoethanolamineGold nanoparticlesSkin inflammationTopical therapeutics

Identifiers

PMID39385245
PMCPMC11465885

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.